Nephros
Nephros, Inc. is a commercial-stage company based in South Orange, New Jersey, specializing in the development and sale of high-performance water purification products for the medical and commercial markets. It operates through two primary segments: Water Filtration and Renal Products. The company's ultrafiltration systems are utilized in dialysis centers to remove biological contaminants from water and bicarbonate concentrate, as well as in hospitals to prevent infections caused by waterborne pathogens like legionella and pseudomonas. Nephros also offers hemodiafiltration systems to enhance treatment options for patients with end-stage renal disease. In the commercial sector, the company provides water filters that enhance water quality by improving taste and reducing contaminants. Founded in 1997, Nephros continues to advance its product offerings, including a second-generation hemodiafiltration system aimed at improving therapies for renal disease patients.
GenArraytion Inc. is a veteran-owned small business based in Rockville, Maryland, specializing in medical diagnostics and molecular genotyping technologies. The company provides a range of products and services focused on the detection and analysis of tick- and mosquito-borne diseases, as well as testing for food and water safety, biodefense, and environmental monitoring. Their innovative offerings include MultiFLEX Bioassays and Sniper Sequencing genotyping services, which facilitate rapid and precise infectious disease assays. GenArraytion has developed advanced technologies such as real-time multiplexed PCR assays, bead-based assays, and custom microarrays that enable the simultaneous detection of multiple pathogens and the antimicrobial characterization of clinically relevant strains. The company is registered in the CCR database and holds ORCA certification, underscoring its commitment to quality and regulatory compliance in its operations.
Biocon Biologics Limited, based in Bengaluru, India, is a subsidiary of Biocon Limited and specializes in the development and manufacturing of biosimilars and novel biologics. Founded in 2016, the company focuses on creating high-quality, affordable biosimilars to enhance patient access to advanced therapies globally. Its product portfolio includes recombinant human insulin, insulin analogs, monoclonal antibodies, and therapeutic proteins aimed at treating various conditions such as diabetes, cancer, and autoimmune diseases. Biocon Biologics operates in multiple markets, including India, the U.S., and Europe, and is committed to the humanitarian responsibility of providing essential drugs through innovative solutions. The company also engages in contract research and manufacturing services through its subsidiary, Syngene, further strengthening its position in the biopharmaceutical sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.